Publication | Open Access

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

VaccinationOpen-label Phase 1Vaccine TargetImmunologyAntiviral Drug DevelopmentVirologyAntibody EngineeringVaccine DesignImmunotherapyMedicineVaccine ResearchEbola Virus GlycoproteinVrc 608